ATE532874T1 - Verfahren zum nachweis in hefe für mittels die proteinfaltung beeinflussen - Google Patents

Verfahren zum nachweis in hefe für mittels die proteinfaltung beeinflussen

Info

Publication number
ATE532874T1
ATE532874T1 AT06024213T AT06024213T ATE532874T1 AT E532874 T1 ATE532874 T1 AT E532874T1 AT 06024213 T AT06024213 T AT 06024213T AT 06024213 T AT06024213 T AT 06024213T AT E532874 T1 ATE532874 T1 AT E532874T1
Authority
AT
Austria
Prior art keywords
disease
protein
yeast
detecting
protein folding
Prior art date
Application number
AT06024213T
Other languages
English (en)
Inventor
Susan Lindquist
Sylvia Krobitsch
Tiago Outeiro
Original Assignee
Univ Chicago
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23026039&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE532874(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Chicago filed Critical Univ Chicago
Application granted granted Critical
Publication of ATE532874T1 publication Critical patent/ATE532874T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
AT06024213T 2001-02-15 2002-02-15 Verfahren zum nachweis in hefe für mittels die proteinfaltung beeinflussen ATE532874T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26915701P 2001-02-15 2001-02-15

Publications (1)

Publication Number Publication Date
ATE532874T1 true ATE532874T1 (de) 2011-11-15

Family

ID=23026039

Family Applications (2)

Application Number Title Priority Date Filing Date
AT02718994T ATE382704T1 (de) 2001-02-15 2002-02-15 Verfahren zum nachweis in hefe für mittels die proteinfaltung beeinflussen
AT06024213T ATE532874T1 (de) 2001-02-15 2002-02-15 Verfahren zum nachweis in hefe für mittels die proteinfaltung beeinflussen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT02718994T ATE382704T1 (de) 2001-02-15 2002-02-15 Verfahren zum nachweis in hefe für mittels die proteinfaltung beeinflussen

Country Status (8)

Country Link
US (7) US7045290B2 (de)
EP (2) EP1392849B2 (de)
JP (2) JP4344138B2 (de)
AT (2) ATE382704T1 (de)
AU (3) AU2002250102B2 (de)
CA (1) CA2438661C (de)
DE (1) DE60224383T3 (de)
WO (1) WO2002065136A2 (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7799535B1 (en) 1997-12-09 2010-09-21 Arch Development Corporation Methods for identifying factors that control the folding of amyloid proteins of diverse origin
DE60224383T3 (de) * 2001-02-15 2012-06-28 The University Of Chicago Verfahren zum nachweis in hefe für mittel die proteinfaltung beeinflussen
ATE500842T1 (de) 2002-05-04 2011-03-15 Acorda Therapeutics Inc Zusammensetzungen und verfahren zur förderung des neuronalen wachstums
AU2003259073A1 (en) * 2002-08-07 2004-02-25 University Of Delaware Compositions and methods for the treatment of diseases exhibiting protein misassembly and aggregation
FR2846008B1 (fr) * 2002-10-18 2006-06-02 Centre Nat Rech Scient Criblage de molecules a activite anti-prion:kits, methodes et molecules criblees
FR2846009B1 (fr) * 2002-10-18 2007-10-12 Centre Nat Rech Scient Criblage de molecules a activite anti-prion:kits, methodes et molecules criblees
JP2007521792A (ja) * 2003-04-16 2007-08-09 ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ 異常に切断されたタンパク質を異所性発現する酵母、およびこの用途
US7959914B2 (en) 2003-05-16 2011-06-14 Acorda Therapeutics, Inc. Methods of reducing extravasation of inflammatory cells
EP3211084B1 (de) * 2003-05-16 2019-03-27 Acorda Therapeutics, Inc. Proteoglycan-abbauende mutanten zur behandlung des zns
ATE393230T1 (de) * 2003-07-11 2008-05-15 Remynd Nv Hefemodell für die toxizität amyloidogener proteine
US7452670B2 (en) 2003-12-04 2008-11-18 University Of Washington Methods of identifying agents that diminish cellular toxicity associated with an α-synuclein polypeptide of Parkinson's disease in yeast
WO2005108599A2 (en) * 2004-05-05 2005-11-17 Whitehead Institute For Biomedical Research Compositions and methods for treatment of protein misfolding diseases
US8226941B2 (en) 2004-05-18 2012-07-24 Acorda Therapeutics, Inc. Methods of purifying chondroitinase and stable formulations thereof
US20110218118A1 (en) * 2004-06-03 2011-09-08 Phylogica Limited Peptide modulators of cellular phenotype and bi-nucleic acid fragment library
NZ588432A (en) 2004-09-17 2012-03-30 Whitehead Biomedical Inst Compounds, Compositions and Methods of Inhibiting Alpha-Synuclein Toxicity
US7618793B2 (en) * 2004-10-20 2009-11-17 The Regents Of The University Of Washington Identifying agents for decreasing cellular toxicity associated with huntingin polypeptide
US7504227B2 (en) * 2004-10-20 2009-03-17 University Of Washington Drug targets for the treatment of neurodegenerative disorders
WO2006073734A2 (en) 2004-12-01 2006-07-13 Whitehead Institute For Biomedical Research Modulator of alpha-synuclein toxicity
WO2006124892A2 (en) 2005-05-13 2006-11-23 Whitehead Institute For Biomedical Research Modulators of alpha-synuclein toxicity
WO2007046882A2 (en) * 2005-06-06 2007-04-26 University Of Maryland, Baltimore County Devices and methods for profiling enzyme substrates
WO2007038548A2 (en) 2005-09-26 2007-04-05 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase abci mutants
BRPI0709699A2 (pt) * 2006-03-29 2011-07-26 Foldrx Pharmaceuticals Inc inibiÇço da toxidez da alfa-sinucleina
GB0610792D0 (en) * 2006-06-02 2006-07-12 Remynd Nv Methods and tools for the screening of factors affecting protein misfolding
CA3009034C (en) 2006-10-10 2020-08-18 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase abci mutants
US8975063B2 (en) 2006-10-19 2015-03-10 California Institute Of Technology Compositions and methods for producing benzylisoquinoline alkaloids
US8323952B2 (en) * 2007-12-13 2012-12-04 Archer Daniels Midland Company Alcoholic xylose fermentation at high temperatures by the thermotolerant yeast Hansenula polymorpha
US8501465B2 (en) 2007-12-21 2013-08-06 Whitehead Institute For Biomedical Research Modulators of alpha-synuclein toxicity
WO2009102995A1 (en) 2008-02-15 2009-08-20 Whitehead Institute For Biomedical Research Yeast cells expressing tar dna-binding protein 43 and uses therefor
WO2010040842A1 (en) * 2008-10-09 2010-04-15 Universitat Autònoma De Barcelona Linking protein aggregation and yeast survival
WO2010111587A1 (en) * 2009-03-26 2010-09-30 Trustees Of The University Of Pennsylvania Modulators of tdp-43 mediated toxicity
US9677079B2 (en) 2010-01-12 2017-06-13 Whitehead Insititute for Biomedical Research Yeast cells expressing amyloid beta and uses therefor
CN101858910B (zh) * 2010-03-25 2013-03-27 辽宁大学 一种在蛋白质水平精确定量检测抗朊病毒药物作用效果的方法
AU2013269270A1 (en) * 2012-06-01 2015-01-15 Oxalys Pharmaceuticals Chemical suppressors of neurotoxicity in synucleinopathic diseases
US10642376B2 (en) 2012-11-28 2020-05-05 Intel Corporation Multi-function stylus with sensor controller
EP3736343A1 (de) 2013-03-15 2020-11-11 Whitehead Institute For Biomedical Research Plattform zur zellulären entdeckung für neurodegenerative erkrankungen
EP2970999A2 (de) 2013-03-15 2016-01-20 The Board Of Trustees Of The University Of the Leland Stanford Junior University Benzylisochinolin-alkaloide (bia) produzierende mikroben sowie verfahren zur herstellung und verwendung davon
US11124814B2 (en) 2013-11-04 2021-09-21 The Board Of Trustees Of The Leland Stanford Junior University Benzylisoquinoline alkaloid (BIA) precursor producing microbes, and methods of making and using the same
CH709681A1 (de) 2014-05-21 2015-11-30 Explo Engineering Ag Pulsdetonationsantrieb.
US9822156B2 (en) 2014-06-13 2017-11-21 Whitehead Institute For Biomedical Research Amyloid beta expression constructs and uses therefor
EP4406549A3 (de) * 2014-07-29 2025-01-08 Neurimmune Holding AG Vom menschen abgeleitete anti-huntingtin-(htt)-antikörper und verwendungen davon
US11261453B2 (en) 2014-09-12 2022-03-01 Whitehead Institute For Biomedical Research Cells expressing apolipoprotein E and uses thereof
CN107002103B (zh) 2014-11-17 2022-01-28 小利兰.斯坦福大学托管委员会 产生类诺斯卡品的微生物以及其制备和使用方法
CA2983419A1 (en) 2015-05-04 2016-11-10 The Board Of Trustees Of The Leland Stanford Junior University Benzylisoquinoline alkaloid (bia) precursor producing microbes, and methods of making and using the same
CN107960102A (zh) 2015-05-08 2018-04-24 小利兰·斯坦福大学托管委员会 产生差向异构酶和苄基异喹啉生物碱的方法
WO2017147536A1 (en) * 2016-02-24 2017-08-31 The Rockefeller University Embryonic cell-based therapeutic candidate screening systems, models for huntington's disease and uses thereof
EA201991650A1 (ru) 2017-01-06 2020-01-20 Юманити Терапьютикс, Инк. Способы лечения неврологических расстройств
EP3583124A1 (de) 2017-02-17 2019-12-25 Bristol-Myers Squibb Company Antikörper gegen alpha-synuklein und verwendungen davon
WO2019028390A1 (en) 2017-08-03 2019-02-07 Antheia, Inc. ALKALOID BENZYLISOQUINOLEIN GENETICALLY MODIFIED EPIMERASES AND METHODS FOR PRODUCING BENZYLISOQUINOLINE ALKALOIDS
US10550550B2 (en) * 2017-09-13 2020-02-04 Dominic P. Ismert Modular two-part sillcock
EP3694536B1 (de) * 2017-10-12 2025-08-27 The Regents of The University of California Zellenbasiertes impfassay zur huntington-aggregation
US10649550B2 (en) 2018-06-26 2020-05-12 Intel Corporation Predictive detection of user intent for stylus use
CA3132968A1 (en) 2019-03-08 2020-09-17 The Board Of Trustees Of The Leland Stanford Junior Unversity Tropane alkaloid (ta) producing non-plant host cells, and methods of making and using the same
US12352719B2 (en) 2019-09-20 2025-07-08 KYCERA AVX Components Corporation Somatic cell-based electrical biosensor
WO2023284782A1 (zh) * 2021-07-14 2023-01-19 复旦大学 筛选用于治疗或预防mHTT相关的神经退行性疾病的化合物的方法，靶蛋白，以及化合物
WO2023137286A1 (en) * 2022-01-12 2023-07-20 Arizona Board Of Regents On Behalf Of Arizona State University Methods and related aspects of quantifying protein stability and misfolding
CN114990049B (zh) * 2022-04-26 2024-01-16 鼎康(武汉)生物医药有限公司 一种同时调节细胞表达产物的糖型和电荷异质性的方法
CN120239749A (zh) 2022-09-29 2025-07-01 安思雅公司 改善吗啡喃生物碱及衍生物的产生的方法
DE202022107272U1 (de) 2022-12-28 2023-01-30 Centurion University of Technology and Management Ein System zur Analyse der Infektion mit Pseudomonas Syringae durch gezielte Ansprache von Cochaperonen, die eine J-Domäne enthalten
WO2024172061A1 (ja) * 2023-02-17 2024-08-22 国立大学法人京都大学 Ｒｎａアプタマー
GB202315164D0 (en) 2023-10-03 2023-11-15 Univ Edinburgh Nanochromosome

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4682195A (en) 1985-09-30 1987-07-21 General Electric Company Insulated gate device with configured emitter contact pad
EP0266032A1 (de) 1986-08-29 1988-05-04 Beecham Group Plc Modifiziertes fibrinolytisches Enzym
US5547841A (en) * 1987-10-08 1996-08-20 The Mclean Hospital Corporation In vitro method for screening for drugs that inhibit production or degradation of human A4-amyloid
AU641434B2 (en) 1989-09-18 1993-09-23 Scios Nova Inc. Assays and reagents for amyloid deposition
GB8921791D0 (en) 1989-09-27 1989-11-08 Imp Cancer Res Tech Disease gene
AU2414092A (en) 1991-08-01 1993-03-02 Paul H. Voorheis Diagnostic method for alzheimer's disease
DE4204650C1 (de) 1992-02-15 1993-07-08 Hoffmeister, Helmut, Dr., 4400 Muenster, De
TW327194B (en) * 1992-05-01 1998-02-21 American Cyanamid Co Novel amyloid precursor proteins and methods of using same
KR940021073A (ko) * 1993-03-02 1994-10-17 미야베 요시가즈 알쯔하이머병의 예방 또는 치료제, 그 스크리닝 방법 및 인간 유래의 타우 단백질 키나아제 i
CA2116280A1 (en) * 1993-03-05 1994-09-06 Marcy E. Macdonald Huntingtin dna, protein and uses thereof
US5643562A (en) 1993-03-29 1997-07-01 Queen's University Of Kingston Method for treating amyloidosis
EP0703984A1 (de) * 1993-04-07 1996-04-03 Cancer Research Campaign Technology Limited Methoden zum Screenen von Substanzen mit therapeutischer Wirkung und Hefewelche dafür verwendet wird
GB9316727D0 (en) 1993-08-12 1993-09-29 Inst Of Psychiatry Models of alzheimers's disease
US5705629A (en) 1995-10-20 1998-01-06 Hybridon, Inc. Methods for H-phosphonate synthesis of mono- and oligonucleotides
US6093549A (en) 1995-11-09 2000-07-25 The Johns Hopkins University Huntingtin-associated protein-related assays
US5928906A (en) 1996-05-09 1999-07-27 Sequenom, Inc. Process for direct sequencing during template amplification
DE69842048D1 (de) 1997-08-01 2011-01-27 Max Planck Gesellschaft Zusammensetzung und verfahren zum nachweis von krankheiten in zusammenhang mit der bildung von amyloid-ähnlichen fibrillen oder protein-aggregaten
US5952217A (en) * 1997-09-23 1999-09-14 Bristol-Myers Squibb Company Recombinant yeast cell and assay using same
US7799535B1 (en) 1997-12-09 2010-09-21 Arch Development Corporation Methods for identifying factors that control the folding of amyloid proteins of diverse origin
US20010006793A1 (en) * 1998-03-20 2001-07-05 Mary-Ann Bjornsti Modulators of eukaryotic caspases
AU4322999A (en) 1998-06-01 1999-12-20 Advanced Research And Technology Institute, Inc. Methods and compositions for diagnosing tauopathies
JP2003504015A (ja) 1999-07-02 2003-02-04 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 神経変性疾患のモデルとしてのトランスジェニック動物
JP2003531570A (ja) * 1999-07-27 2003-10-28 アブジェニックス インク． 神経障害に関連したポリペプチド蓄積を阻害する方法および組成物
US6420122B1 (en) * 1999-09-27 2002-07-16 Massachusetts Institute Of Technology Methods of screening for agents that inhibit aggregation of polypeptides
AU783144B2 (en) 2000-02-21 2005-09-29 H. Lundbeck A/S Novel method for down-regulation of amyloid
IT1317922B1 (it) 2000-10-24 2003-07-15 S I S S A Scuola Internaz Supe Metodo per identificare in vivo epitopi intracellulari.
DE60224383T3 (de) * 2001-02-15 2012-06-28 The University Of Chicago Verfahren zum nachweis in hefe für mittel die proteinfaltung beeinflussen
GB0104685D0 (en) * 2001-02-26 2001-04-11 Leuven K U Res & Dev Tau-opathy model
WO2003000853A2 (en) 2001-06-20 2003-01-03 Caprion Pharmaceuticals Inc. Protein aggregation assays and uses thereof
ATE393230T1 (de) 2003-07-11 2008-05-15 Remynd Nv Hefemodell für die toxizität amyloidogener proteine

Also Published As

Publication number Publication date
AU2011200744B2 (en) 2013-04-04
CA2438661C (en) 2011-05-31
CA2438661A1 (en) 2002-08-22
EP1392849B1 (de) 2008-01-02
JP2008259509A (ja) 2008-10-30
EP1392849A2 (de) 2004-03-03
AU2007221933B2 (en) 2010-12-16
AU2002250102B2 (en) 2007-07-12
US20060147902A1 (en) 2006-07-06
JP4344138B2 (ja) 2009-10-14
JP2004537973A (ja) 2004-12-24
US8039209B2 (en) 2011-10-18
EP2319936A3 (de) 2012-10-17
US20170306386A1 (en) 2017-10-26
WO2002065136A3 (en) 2003-12-11
DE60224383D1 (de) 2008-02-14
WO2002065136A2 (en) 2002-08-22
EP2319936A2 (de) 2011-05-11
ATE382704T1 (de) 2008-01-15
US9518284B2 (en) 2016-12-13
US20140273074A1 (en) 2014-09-18
EP1392849B2 (de) 2012-01-18
US20110300533A1 (en) 2011-12-08
AU2011200744A1 (en) 2011-03-17
JP5152977B2 (ja) 2013-02-27
US20030073610A1 (en) 2003-04-17
US20130005608A1 (en) 2013-01-03
US20060141449A1 (en) 2006-06-29
DE60224383T2 (de) 2009-01-08
DE60224383T3 (de) 2012-06-28
AU2007221933A1 (en) 2007-11-01
US7045290B2 (en) 2006-05-16

Similar Documents

Publication Publication Date Title
ATE532874T1 (de) Verfahren zum nachweis in hefe für mittels die proteinfaltung beeinflussen
WO2008068024A3 (en) Means and methods for isolating and determining novel targets for the treatment of neurodegenerative, neurological or neuropsychiatric disorders and compositions comprising the same
WO2003042654A3 (en) Multi-parameter high throughput screening assays (mphts)
EP1922325A4 (de) Methoden für die diagnose von demenz und anderen neurologischen erkrankungen
IL154794A0 (en) Remedies for heart failure
BRPI0513029A (pt) método para produzir uma proteìna de eritropoietina carbamilada, proteìna de eritropoietina carbamilada, composto, composição farmacêutica, métodos de tratamento de uma doença ou condição crÈnica, sub-crÈnica e aguda e de tratamento de uma doença do sistema nervoso central ou sistema nervoso periférico, e, uso de um composto
AU4929701A (en) Whole-body optical imaging of gene expression and uses thereof
ATE361067T1 (de) Naphtoquinone derivate als inhibitoren von tau aggregation zur behandlung von alzheimer's und verbundenen neurodegenerativen erkrankungen
AU1618000A (en) Use of radioligands to screen inhibitors of amyloid-beta peptide production
ATE548453T1 (de) Material und methoden, involviert in die protein- aggregation neurodegenerativer krankheiten
ATE526981T1 (de) Verwendung von vegf 165 und homologen zur behandlung von neurologischen störungen
AU2003259222A1 (en) Method of diagnosing alzheimer's disease
ATE465408T1 (de) Verfahren zur diagnose und überwachung von neurologischen erkrankungen durch nachweis eines encephalotoxins
ATE323539T1 (de) Chromatographie-verfahren und vorrichtung welche einen konzentrations-schritt integrieren
ATE347698T1 (de) Verfahren zum nachweis von alzheimer-krankheit
ATE462140T1 (de) Verfahren zum nachweis aggregatbildender zirkulierender proteinformen und mittel zum einfangen gebildeter aggregate
EP1793001A3 (de) Verfahren zum Nachweis in Hefe für mittels die Proteinfaltung beeinflussen
WO2004005882A3 (en) Multi-parameter high throughput screening assays (mphts)
ATE495269T1 (de) Adarb2 proteine als diagnostische und therapeutische targets für neurodegenerative erkrankungen
WO2006091964A3 (en) Regulators of protein misfolding and aggregation and methods of using the same
WO2004074245A3 (en) Monkey alpha-7 nicotinic acetylcholine receptor and methods of use thereof
WO2003087408A3 (en) Schizophrenia associated genes
WO2005038463A8 (en) Method for the detection of a neurological or psychiatric, demential disease, especially alzheimer's disease by use of cholecystokinin (cck) -molecules, corresponding substances and detection reagents
WO2006029838A3 (en) Secreted polypeptide species involved in alzheimer’s disease
ATE316657T1 (de) Diagnostische und therapeutische verwendung des caps